ArticleAntibody therapeutics2021

Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors.

Hu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.